EMA Authorised: Ambrisentan Viatris (previously Ambrisentan Mylan) (ambrisentan) — Viatris Limited

View source ↗

Summary

The EMA authorised Ambrisentan Viatris (ambrisentan) for pulmonary arterial hypertension, with Viatris Limited as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ambrisentan Viatris (ambrisentan)

Snippet

Status: Authorised. Therapeutic area: Hypertension, Pulmonary. MAH: Viatris Limited. Decision date: 15/12/2025